sorafenib increases 18-fdg colic uptake demonstration in patients with differentiated thyroid cancer索拉非尼增加18-fdg绞痛吸收示范分化型甲状腺癌患者.pdfVIP

sorafenib increases 18-fdg colic uptake demonstration in patients with differentiated thyroid cancer索拉非尼增加18-fdg绞痛吸收示范分化型甲状腺癌患者.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
sorafenib increases 18-fdg colic uptake demonstration in patients with differentiated thyroid cancer索拉非尼增加18-fdg绞痛吸收示范分化型甲状腺癌患者

Ciappuccini et al. EJNMMI Research 2012, 2:18 /content/2/1/18 SHORT COMMUNICATION Open Access Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer 1* 2 3 4 Renaud Ciappuccini , Géraldine Trzepla , Natacha Heutte , Emmanuel Sevin , Marie Pierre Galais4 and Stéphane Bardet1 Abstract Background: To assess 18-fluorodeoxyglucose (FDG) bowel uptake in patients with differentiated thyroid cancer (DTC) treated with sorafenib. Findings: Visual (5-point scale) and high maximum standard uptake value (SUVmax) semi-quantitative analyses were conducted in 63 positron emission tomography (PET) studies performed in patients on sorafenib (group 1, n = 20), in a control group (group 2, n = 28) and in patients on sunitinib or vandetanib (group 3, n = 15). Moderate or high and diffuse bowel uptake (grade 4 or 5) was observed in 90% of the PET scans of group 1 versus none in group 2. Only 20% of PET scans in group 3 were scored grade 4. SUVmax values were significantly higher for all colic segments in group 1 than in group 2 (P 0.0001) or 3 (P 0.0004). This uptake pattern appeared rapidly (one month) and disappeared after sorafenib withdrawal. Conclusions: FDG uptake is increased in the colon of DTC patients treated by sorafenib. Keywords: Sorafenib, FDG PET, Thyroid cancer, Colic uptake Findings patients treated by other TKI such as sunitinib and Background vandetanib. Sorafenib is a new targeted therapy with an angiogenesis inhibiting activity, belonging to the tyrosine kinase inhi- Methods bitors (TKI) family [1]. This multikinase inhibi

您可能关注的文档

文档评论(0)

118zhuanqian + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档